GlassScriptPhysician profile
Marty Phillip Dack
NPI 1871686337
$2,641.51
in general payments reported to CMS, 2019-2025
27 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.10 · 2022: $59.68 · 2023: $651 · 2024: $783 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.13 |
| Education | $239.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $349.34 | 2023-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $231.23 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $214.24 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $205.40 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $187.78 | 2023-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $154.96 | 2023-2024 | |
| Opko Pharmaceuticals, LLC | $154.79 | 2023-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $146.51 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Lilly USA, LLC | $136.84 | 2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $127.55 | 2024-2025 | Airsupra, Farxiga |
| Akebia Therapeutics INC | $125.66 | 2021-2025 | Vafseo |
| Ardelyx, INC. | $100.17 | 2024 | Ibsrela |
| Novo Nordisk INC | $86.25 | 2024-2025 | Ozempic, Rybelsus |
| Apellis Pharmaceuticals, INC. | $75.99 | 2025 | Empaveli |
| Alnylam Pharmaceuticals INC. | $51.12 | 2024-2025 | Onpattro, Oxlumo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $46.46 | 2024-2025 | Jynarque |
| Baxter Healthcare | $37.33 | 2023 | Renal - Amia |
| Aurinia Pharma U.S., INC. | $35.13 | 2022-2023 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $32.20 | 2023 | Gattex |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.03 | 2025 | |
| Scpharmaceuticals INC. | $18.86 | 2025 | |
| Kyowa Kirin, INC. | $18.41 | 2025 | |
| Glaxosmithkline, LLC. | $16.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.84 | 2025 | Jardiance |
| Pfizer INC. | $16.62 | 2024 | |
| Horizon Therapeutics Plc | $16.43 | 2023 | Krystexxa |
| Boston Scientific Corporation | $16.40 | 2023 | Watchman |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marty Dack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.